Methotrexate and cardiovascular risk in rheumatic diseases:A comprehensive review.

Verhoeven F, Prati C, Chouk M, Demougeot C, Wendling D

Open source

DOI
10.1080/17512433.2021.1932461
Published
2021 Sep
Container
Expert review of clinical pharmacology
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/17512433.2021.1932461,
  title = {Methotrexate and cardiovascular risk in rheumatic diseases:A comprehensive review.},
  author = {Verhoeven F and Prati C and Chouk M and Demougeot C and Wendling D},
  year = {2021},
  journal = {Expert review of clinical pharmacology},
  doi = {10.1080/17512433.2021.1932461},
  url = {https://doi.org/10.1080/17512433.2021.1932461}
}

RIS

TY  - JOUR
TI  - Methotrexate and cardiovascular risk in rheumatic diseases:A comprehensive review.
AU  - Verhoeven F
AU  - Prati C
AU  - Chouk M
AU  - Demougeot C
AU  - Wendling D
PY  - 2021
JO  - Expert review of clinical pharmacology
DO  - 10.1080/17512433.2021.1932461
UR  - https://doi.org/10.1080/17512433.2021.1932461
ER  - 

APA

F, V., C, P., M, C., C, D., & D, W. (2021). Methotrexate and cardiovascular risk in rheumatic diseases:A comprehensive review.. Expert review of clinical pharmacology. https://doi.org/10.1080/17512433.2021.1932461

Source records